Business Details
10 Years
experience
AI-Driven CT FFR Analysis for Cardiovascular Care
Keya Medical is an international medical technology company dedicated to advancing cardiovascular diagnostics through artificial intelligence. Founded in 2016, we specialize in deep learning-based solutions that address critical challenges in coronary artery disease diagnosis and management. Our flagship product, DEEPVESSEL FFR, represents a groundbreaking innovation in non-invasive CT fractional flow reserve analysis, offering clinicians precise physiological assessments of coronary arteries. With FDA clearance, CE marking, NMPA approval, and HSA certification, our technology has been validated through extensive clinical trials involving over 500 patients globally. We collaborate with leading medical institutions and experts, including partnerships with Corazon Imaging and integration into Bayer's Calantic AI platform, to deliver solutions that reduce unnecessary invasive procedures by up to 30% while improving patient outcomes.Our commitment to innovation is reflected in our comprehensive R&D pipeline, which spans the entire patient care continuum from early screening to post-treatment follow-up. With strategic funding exceeding $100 million and a growing portfolio of registered patents, we maintain ISO 13485 certification standards while operating through secure cloud platforms like Ambra Intelerad to ensure timely, reliable service delivery across hospital outpatient facilities, physician offices, and imaging centers worldwide.
Services
DEEPVESSEL FFR
CT FFR Analysis
AI Medical Solutions
Cardiovascular Diagnostics
Coronary Artery Assessment
Details
- Year established: 2016
Highlights and features
- We offer FDA-cleared, CE-marked AI solutions for cardiovascular diagnosis
- Our team has over a decade of experience in AI medical technologies
- We provide 24/7 personalized customer support
- Our solutions reduce unnecessary invasive testing by up to 30%
- We operate with full transparency and no hidden fees
Associations and certifications
- ISO 13485
- FDA
- CE Mark
- NMPA
- HSA
What people say
Transformed my practice
Superior patient care
Accurate results
User-friendly interface
Enhanced decision-making
Services
DEEPVESSEL FFR
DEEPVESSEL FFR provides non-invasive physiological assessment of coronary arteries using AI-powered CT angiography. This technology enables clinicians to evaluate blood flow restrictions in coronary vessels without invasive procedures. Backed by FDA clearance and extensive clinical validation, it offers 86.8% diagnostic accuracy while reducing unnecessary catheterizations.
AI Medical Solutions
Our AI solutions transform cardiovascular diagnostics through deep learning algorithms trained on thousands of clinical cases. These tools enhance diagnostic precision, streamline workflow efficiency, and support evidence-based decision-making for improved patient outcomes in coronary artery disease management.
Cardiovascular Diagnostics
We offer advanced diagnostic solutions for coronary artery disease assessment, combining anatomical imaging with functional analysis. Our technology helps identify hemodynamically significant lesions, enabling early intervention and personalized treatment planning for patients with suspected cardiovascular conditions.
Coronary Artery Assessment
Our assessment tools create detailed 3D coronary artery models with mapped FFR values, providing comprehensive insights into both anatomical stenosis and functional blood flow impact. This dual assessment improves diagnostic confidence and treatment decision-making.
Clinical Workflow Integration
We provide seamless integration with existing imaging platforms through secure cloud-based systems. Our solutions require no additional scanner certification or staff training, delivering rapid results while maintaining compatibility with hospital IT infrastructure and regulatory requirements.
People
John A. Rumberger
Medical Director
PhD, MD, FACC, MSCCT with 30+ years of cardiovascular imaging experience. Former Mayo Clinic professor and Princeton Longevity Center director, published nearly 500 research papers, and established the International Society of Atherosclerosis Imaging.
Questions
What is DEEPVESSEL FFR?
DEEPVESSEL FFR is an FDA-cleared AI solution that provides non-invasive CT fractional flow reserve analysis for assessing coronary artery disease severity.
How does CT FFR work?
CT FFR combines coronary CT angiography with AI algorithms to create 3D models and simulate blood flow measurements across the entire coronary tree.
What are the benefits of using DEEPVESSEL FFR?
It reduces unnecessary invasive procedures by up to 30%, improves diagnostic accuracy, and enables faster clinical decision-making.
Where is DEEPVESSEL FFR available?
Available in the USA, Europe, China, and Singapore, with secure cloud-based analysis accessible on mobile and desktop devices.
How accurate is DEEPVESSEL FFR?
Clinical trials show 86.8% overall accuracy compared to invasive FFR, with 86.9% sensitivity and 86.7% specificity.
Is CT FFR covered by insurance?
Yes, with the new CPT code 75580, CT FFR services are reimbursable by Medicare and private insurers in hospital outpatient settings.
Videos
